![]() |
市場調查報告書
商品編碼
2082034
伴侶動物保健市場:2026-2032年全球市場預測(依動物種類、產品類型、劑型、通路和治療領域分類)Companion Animal Health Market by Animal Type, Product Type, Formulation, Distribution Channel, Therapeutic Area - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,伴侶動物健康市場將成長至 436.7 億美元,複合年成長率為 8.66%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 244億美元 |
| 預計年份:2026年 | 264.5億美元 |
| 預測年份 2032 | 436.7億美元 |
| 複合年成長率 (%) | 8.66% |
隨著寵物飼主越來越將犬、貓和其他伴侶動物視為家庭成員,伴侶動物健康市場正在不斷擴大。市場需求主要集中在動物用藥品、疫苗、驅蟲藥、診斷試劑、營養補充品、疼痛管理產品、皮膚病治療產品、牙科護理產品、外科手術產品和數位化獸醫服務等方面。
檢驗的行業指標支持了該行業的韌性。根據美國寵物用品協會 (APPA) 統計,2023 年美國寵物產業支出約為 1,470 億美元,其中獸醫護理及相關產品仍是主要類別。在歐洲,歐洲寵物及動物保健聯合會 (FEDIAF) 的數據持續反映著數百萬家庭養寵的現狀,推動了對預防性護理、慢性病管理以及循證伴侶動物健康解決方案的需求。
伴侶動物醫療保健領域正從一次性治療轉向預防性、持續性和數據驅動的獸醫護理。寵物飼主越來越希望獲得早期診斷、健康計劃、寄生蟲預防、營養指導和治療,以提高老年動物的生活品質。獸醫診所也正在採用即時診斷、臨床管理平台和一體化藥局服務,以提高臨床效率。
人工智慧(AI)不再只是曇花一現的潮流,它正成為伴侶動物健康整體的實用工具。 AI驅動的影像診斷、檢測結果解讀、臨床決策支援和遠端分診,能夠幫助獸醫確定病例優先順序、減輕行政負擔,並提高日常工作流程的效率。
在亞太地區,隨著都市化、可支配收入的增加以及寵物「人性化」的推進,對疫苗、診斷、營養和獸醫服務的需求不斷成長,其中中國、印度、日本、韓國和澳洲是成長的主要驅動力。北美地區仍然是寵物市場最成熟的地區之一,這得益於其較高的寵物擁有率、先進的獸醫基礎設施、高於許多其他地區的寵物保險普及率以及專科藥物的快速普及。
東協市場對伴侶動物的疫苗、營養產品、診斷試劑和零售獸醫服務的需求日益成長,但監管差異導致市場准入計畫必須因地制宜。海灣合作理事會(GCC)地區的特點是高階獸藥產品主導進口,專科診所數量不斷增加,且都市區的飼主願意為寵物支付高水準的醫療服務費用。
美國在伴侶動物消費、專科獸醫護理、診斷和創新商業化方面處於主導。而加拿大則更注重預防保健、專科獸醫標準和基於監管的產品品質。墨西哥和巴西是拉丁美洲的重要市場,這得益於都市區寵物擁有率的上升、獸醫網路的擴展、疫苗接種需求的成長以及寄生蟲預防藥物使用量的增加。
行業領導者應優先考慮與已證實的臨床需求相符的產品系列,包括預防醫學、皮膚病學、疼痛管理、驅蟲藥、疫苗、診斷、口腔健康、營養和慢性病監測。銷售團隊不僅應透過消費者行銷來支援獸醫,還應提供基於實證醫學、教育性、藥物安全監測和工作流程相關的工具。
本執行摘要基於來自獸醫監管機構、動物健康協會、同行評審文獻、行業數據以及有關寵物飼養的可靠資訊來源的多方面二手研究,包括 APPA、FEDIAF、FDA CVM、EMA、WOAH 和國家獸醫機構。
隨著寵物照護日益人性化,預防醫學、獸醫創新和數位化照護不斷融合,伴侶動物健康領域預計將持續擴張。該市場不再僅限於藥物和門診就診,而是涵蓋了綜合診斷、營養管理、監測、遠端醫療支援、保險覆蓋的護理以及數據驅動的護理路徑。
The Companion Animal Health Market is projected to grow by USD 43.67 billion at a CAGR of 8.66% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 24.40 billion |
| Estimated Year [2026] | USD 26.45 billion |
| Forecast Year [2032] | USD 43.67 billion |
| CAGR (%) | 8.66% |
The companion animal health market is expanding as pet owners increasingly treat dogs, cats, and other companion animals as members of the family. Demand is concentrated across veterinary pharmaceuticals, vaccines, parasiticides, diagnostics, nutrition, pain management, dermatology, dental care, surgical products, and digital veterinary services.
Verified industry indicators support the sector's resilience. The American Pet Products Association reported U.S. pet industry expenditures of about USD 147 billion in 2023, with veterinary care and product spending remaining a major category. In Europe, FEDIAF data continue to show pet ownership across millions of households, reinforcing demand for preventive care, chronic disease management, and evidence-based companion animal health solutions.
The companion animal health landscape is shifting from episodic treatment toward preventive, continuous, and data-enabled veterinary care. Pet owners are seeking earlier diagnostics, wellness plans, parasite prevention, nutrition guidance, and therapies that improve quality of life for aging animals. Veterinary clinics are also adopting point-of-care diagnostics, practice-management platforms, and integrated pharmacy services to improve clinical efficiency.
Innovation is accelerating in monoclonal antibodies, long-acting parasiticides, dermatology, osteoarthritis pain management, vaccines, and specialty diagnostics. At the same time, veterinary workforce shortages, cost sensitivity, and regulatory scrutiny from agencies such as the U.S. FDA Center for Veterinary Medicine and the European Medicines Agency are reshaping product development, access, and commercialization strategies.
Artificial intelligence is becoming a practical capability across companion animal health rather than a standalone trend. AI-enabled imaging review, laboratory result interpretation, clinical decision support, and tele-triage can help veterinarians prioritize cases, reduce administrative burden, and improve consistency in routine workflows.
The strongest near-term value lies in augmenting veterinary professionals, not replacing them. AI tools can support wearable-based monitoring, early disease detection, inventory forecasting, pharmacovigilance, and personalized care reminders. However, adoption depends on validated algorithms, transparent data governance, cybersecurity, clinician oversight, and compliance with veterinary medical standards.
Asia-Pacific is gaining momentum as urbanization, rising disposable income, and pet humanization increase demand for vaccines, diagnostics, nutrition, and clinic services, with China, India, Japan, South Korea, and Australia serving as distinct growth engines. North America remains one of the most mature regions, supported by high pet ownership, advanced veterinary infrastructure, strong pet insurance adoption compared with many regions, and rapid uptake of specialty therapeutics.
Latin America is advancing through expanding private veterinary networks in Brazil and Mexico, while Europe benefits from established animal welfare standards, sophisticated regulation, and strong preventive care adoption. The Middle East, especially high-income Gulf markets, is seeing premiumization in companion animal services, including specialty clinics and imported therapeutics. Africa remains more access-driven, with opportunities tied to vaccination, parasite control, rabies prevention, affordable diagnostics, and broader veterinary service availability.
ASEAN markets show rising demand for companion animal vaccines, nutrition, diagnostics, and retail veterinary services, although regulatory fragmentation requires localized market-entry planning. The GCC is characterized by import-driven premium veterinary products, growing specialty clinics, and owners willing to pay for advanced care in urban centers.
The European Union offers harmonized regulatory pathways, high animal welfare expectations, and strong demand for proven safety and efficacy. BRICS countries provide scale through large pet populations and expanding middle-class ownership, but pricing, access, and veterinary infrastructure vary widely. G7 markets anchor innovation, clinical standards, specialty therapeutics, and digital veterinary adoption, while NATO countries add relevance through biosecurity, working-dog health, supply-chain resilience, and coordinated animal health preparedness.
The United States leads in companion animal spending, specialty veterinary care, diagnostics, and innovation commercialization, while Canada emphasizes preventive care, professional veterinary standards, and regulated product quality. Mexico and Brazil are important Latin American markets, supported by growing urban pet ownership, expanding clinic networks, vaccination demand, and increasing use of parasite prevention.
In Europe, the United Kingdom, Germany, France, Italy, and Spain combine high pet ownership with advanced veterinary services, strong retail channels, and preventive medicine adoption, while Russia remains a sizable but complex market influenced by access, regulation, and trade conditions. In Asia-Pacific, China and India offer scale through expanding pet populations and rising urban ownership, Japan and South Korea show strong premiumization and advanced clinic standards, and Australia is notable for high pet ownership, preventive care, biosecurity awareness, and mature clinical practices.
Industry leaders should prioritize portfolios that align with verified clinical need: preventive care, dermatology, pain management, parasiticides, vaccines, diagnostics, dental health, nutrition, and chronic disease monitoring. Commercial teams should support veterinarians with evidence, education, pharmacovigilance, and workflow-friendly tools rather than relying only on consumer marketing.
Companies should validate AI and digital health tools in real-world veterinary settings, build compliant data systems, and localize pricing, packaging, and distribution by region. Partnerships with clinics, diagnostic laboratories, insurers, e-commerce platforms, shelters, and academic institutions can improve access while strengthening trust in companion animal health brands.
This executive summary is based on triangulated secondary research from veterinary regulatory agencies, animal health associations, peer-reviewed literature, trade data, and recognized pet ownership sources, including APPA, FEDIAF, FDA CVM, EMA, WOAH, and national veterinary bodies.
Insights were developed by comparing demand indicators such as pet ownership, veterinary expenditure, clinic infrastructure, product approvals, disease-prevention priorities, insurance penetration, regulatory requirements, and digital adoption. Regional, group, and country assessments emphasize verified structural drivers rather than unsubstantiated forecasts, market sizing, or market share assumptions.
Companion animal health is positioned for durable expansion as pet humanization, preventive medicine, veterinary innovation, and digital care converge. The market is no longer defined only by pharmaceuticals or clinic visits; it now includes integrated diagnostics, nutrition, monitoring, telehealth support, insurance-enabled care, and data-enabled care pathways.
Organizations that combine scientific credibility, regulatory discipline, veterinarian-centered commercialization, and responsible AI adoption will be best positioned to capture long-term value. The strongest opportunities will come from improving access, outcomes, affordability, and trust across diverse global pet care markets.